Who
Jung Choi
Director
Company insider
Files Form 4 as: Director, Annexon; Officer, Global Blood Therapeutics.
In numbers
- Trades disclosed
- 238
- Buys
- 3
- Sells
- 11
- Bought
- $1.1M
- Sold
- $1.4M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 17 Aug 2015
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 1 Dec 2025filed 3 Dec 2025 | ANNX AnnexonBiotechnology | SEC FORM 4 Bought | $138K33,000 at $4.19 | filing |
| 5 Jun 2025filed 9 Jun 2025 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 8 Jun 2023filed 12 Jun 2023 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —3,125 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —9,060 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —13,814 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —15,460 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —26,454 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —42,400 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —1 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —1 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —32,098 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —35,000 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —40,000 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —36,225 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —38,739 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —28,628 | filing |
News
No headline names them, or the companies they trade most, lately.